S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

Aphria Stock Price, Forecast & Analysis (NYSE:APHA)

$4.52
+0.21 (+4.87 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$4.36
Now: $4.52
$4.66
50-Day Range
$3.84
MA: $4.95
$5.60
52-Week Range
$3.75
Now: $4.52
$10.95
Volume8.11 million shs
Average Volume5.35 million shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.83
Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$179.29 million

Profitability

Miscellaneous

Employees300
Market Cap$1.14 billion
Next Earnings Date1/10/2020 (Estimated)
OptionableNot Optionable

Receive APHA News and Ratings via Email

Sign-up to receive the latest news and ratings for APHA and its competitors with MarketBeat's FREE daily newsletter.


Aphria (NYSE:APHA) Frequently Asked Questions

What is Aphria's stock symbol?

Aphria trades on the New York Stock Exchange (NYSE) under the ticker symbol "APHA."

How were Aphria's earnings last quarter?

Aphria Inc (NYSE:APHA) released its quarterly earnings data on Tuesday, October, 15th. The company reported $0.07 EPS for the quarter, beating the Zacks' consensus estimate of ($0.03) by $0.10. The firm earned $126.10 million during the quarter, compared to the consensus estimate of $131.15 million. The business's quarterly revenue was up 848.1% on a year-over-year basis. View Aphria's Earnings History.

When is Aphria's next earnings date?

Aphria is scheduled to release their next quarterly earnings announcement on Friday, January 10th 2020. View Earnings Estimates for Aphria.

What guidance has Aphria issued on next quarter's earnings?

Aphria issued an update on its FY 2020 earnings guidance on Tuesday, October, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $650-700 million.

What price target have analysts set for APHA?

9 brokerages have issued 12-month target prices for Aphria's stock. Their forecasts range from $6.50 to $22.75. On average, they expect Aphria's stock price to reach $12.12 in the next year. This suggests a possible upside of 168.1% from the stock's current price. View Analyst Price Targets for Aphria.

What is the consensus analysts' recommendation for Aphria?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aphria in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aphria.

What are Wall Street analysts saying about Aphria stock?

Here are some recent quotes from research analysts about Aphria stock:
  • 1. According to Zacks Investment Research, "Aphria Inc. produces, supplies and sells medical cannabis primarily in Canada. The company offers sativa, indica and hybrid medical marijuana products, as well as cannabis oils. Aphria Inc. is headquartered in Leamington, Canada. " (11/13/2019)
  • 2. Clarus Securities analysts commented, "We had previously assumed a run-rate of ~$865MM by the end of CY2020; we are now in line with management’s target." (4/16/2019)

Has Aphria been receiving favorable news coverage?

Media headlines about APHA stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aphria earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Aphria.

Are investors shorting Aphria?

Aphria saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 32,710,000 shares, an increase of 26.4% from the September 15th total of 25,870,000 shares. Based on an average daily volume of 5,530,000 shares, the days-to-cover ratio is currently 5.9 days. Approximately 14.1% of the shares of the stock are short sold. View Aphria's Current Options Chain.

Who are some of Aphria's key competitors?

What other stocks do shareholders of Aphria own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), NVIDIA (NVDA), HEXO (HEXO), Charlotte's Web (CWBHF), KushCo (KSHB), OrganiGram (OGI) and Aurora Cannabis (ACB).

Who are Aphria's key executives?

Aphria's management team includes the folowing people:
  • Mr. Carl A. Merton, Chief Financial Officer
  • Ms. Megan McCrae, Director of Marketing
  • Mr. Irwin D. Simon, Interim CEO & Chairman
  • Mr. Jakob Ripshtein, Pres
  • Mr. Gary Leong, Chief Science Officer (Age 54)

Who are Aphria's major shareholders?

Aphria's stock is owned by many different of institutional and retail investors. Top institutional investors include CIBC Asset Management Inc (0.06%), Creative Planning (0.03%), Commerzbank Aktiengesellschaft FI (0.03%), Exane Derivatives (0.02%), Cambridge Investment Research Advisors Inc. (0.01%) and Great West Life Assurance Co. Can (0.01%).

Which institutional investors are selling Aphria stock?

APHA stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, Great West Life Assurance Co. Can and AE Wealth Management LLC.

Which institutional investors are buying Aphria stock?

APHA stock was bought by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Cambridge Investment Research Advisors Inc., CIBC Asset Management Inc, Signition LP, First Allied Advisory Services Inc., Wedbush Securities Inc., Sfmg LLC and Creative Planning.

How do I buy shares of Aphria?

Shares of APHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aphria's stock price today?

One share of APHA stock can currently be purchased for approximately $4.52.

How big of a company is Aphria?

Aphria has a market capitalization of $1.14 billion and generates $179.29 million in revenue each year. Aphria employs 300 workers across the globe.View Additional Information About Aphria.


MarketBeat Community Rating for Aphria (NYSE APHA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about Aphria and other stocks. Vote "Outperform" if you believe APHA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel